Technology
The Company has strong proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines.
Multiple recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development. HBI also has a robust drug discovery and development program producing medical countermeasure small molecule anti-toxin drugs.
HBI also owns a saponin adjuvant, GPI-0100, which is useful in helping to elicit broad immune responses to certain vaccines and therapeutics especially in cancer. HBI has licensed the rights for use of the adjuvant on a non-exclusive basis to third parties, (including for use with certain animal health and cancer vaccines) and is open to additional licensing opportunities for GPI-0100.
The Company has strong proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines.
Multiple recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development. HBI also has a robust drug discovery and development program producing medical countermeasure small molecule anti-toxin drugs.
HBI also owns a saponin adjuvant, GPI-0100, which is useful in helping to elicit broad immune responses to certain vaccines and therapeutics especially in cancer. HBI has licensed the rights for use of the adjuvant on a non-exclusive basis to third parties, (including for use with certain animal health and cancer vaccines) and is open to additional licensing opportunities for GPI-0100.